Linked Life Data

21813753

Source:http://linkedlifedata.com/resource/pubmed/id/21813753

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
94
pubmed:dateCreated
2011-8-4
pubmed:abstractText
Hepatitis C virus (HCV) infection in humans can cause progressive and end-stage liver disease. As such, preventive measures against HCV, including vaccine development, are a priority among researchers in the field. The report from Garrone et al. describes the development of a vaccine platform to generate HCV-neutralizing antibodies that are based on retrovirus-derived virus-like particles (VLPs) pseudotyped with heterologous viral envelope proteins. Immunization with these VLPs induced neutralizing antibodies in mouse and macaque models. These results, when considered in the context of an earlier clinical trial that used recombinant HCV E1/E2 purified protein as a subunit vaccine and additional findings from the VLP strategy, may lead to a new HCV vaccine that induces a neutralizing antibody response.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1946-6242
pubmed:author
pubmed:issnType
Electronic
pubmed:day
3
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
94ps33
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Progress toward development of a hepatitis C vaccine with broad shoulders.
pubmed:affiliation
Department of Internal Medicine, Saint Louis University, Saint Louis, MO 63104, USA. rayr@slu.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural